Laverock Therapeutics Ltd. (formerly Skylark Therapeutics) recently completed a seed funding round to support its development of a unique gene silencing platform for the creation of programmable, allogeneic cell therapies.
Sichuan Jinjiang Electronic Science and Technology Co. Ltd. (JJET) recently completed series A+ and series B rounds, raising a total of ¥700 million (US$101 million) in series A and series B financing.
Taiwan’s Brim Biotechnology Inc. announced a capital raise of $18 million to advance its lead candidate, regenerative peptide therapy BRM-421, to phase III trials for dry eye syndrome. It’s designed to offer relief from dry eye symptoms by stimulating proliferation and differentiation of stem cells to repair damage to the cornea. “Our goal is restoration and repair of the damage caused by DES,” said Brim founder and CEO Haishan Jang.
Ocean Biomedical Inc., a company with preclinical programs in oncology, fibrosis, infectious disease treatments and vaccines, is poised to go public via a merger with Aesther Healthcare Acquisition Corp., a special purpose acquisition company (SPAC).
Astrivax BV has raised €30 million (US$30.1 million) in a seed round to take forward the development of a novel vaccine technology that combines a plasmid vector with a replication-competent virus.
Australian radiopharmaceutical company Advancell Co. Ltd. closed an AU$18 million (US$12.4 million) series B round that will take its lead targeted alpha-emitting radiotherapy, ADVC-001, for metastatic prostate cancer to the clinic by the end of 2022.
RSS
